MabThera

Active ingredient
Rituximab
Pharma Company
Roche Pharma AG/ Roche Deutschland Holding GmbH
Total Number of Doctors1
605 doctors
Total Number of Patients2
9,140 patients
Total minimum fees planned3
4,346,680.00 €

Observational Studies including MabThera

Drug No. of doctors1 No. of patients2 Payment per patient3
MabThera n/a 1,250 277.00 € retrospektive Datenerhebung über 12 m
MabThera 45 1,076 830.00 € bis 1790,00: 70€/h zugrundegelegt, DLBCL: 8 Zyklen , fNHL: 20 Zyklen
MabThera 28 n/a 660.00 € 7 Visiten
MabThera, Enbrel, Humira, Remicade 14 55 240.00 € s. detaillierte Aufschlüsselung
MabThera 117 700 575.00 € pro ordnungsgemäß ausgefülltem Dokumentationsbogen, bei Ablieferung der vereinbarten maximalen 5 Dokumentationsbögen =2.500 €
MabThera 139 500 685.00 € first-line, 515 + 80 rezidiv.
MabThera 46 229 250.00 € pro ausgefüllten Dokumentationsbogen, bei max. 40 Dokumentationsbogen = 10.000 €
MabThera 216 5,330 430.00 € max. pro Patient bei vollständige Dokumentation der Behandlungsdaten, aufgeschlüsselt im Vertrag

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.